Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Significant progress has been made in the development of a new vaccine against Staphylococcus aureus infections.
Intervacc AB enters into a commercial production phase with Strangvac®.
Intervacc conducts share issue, directed to both previous and new investors
Intervacc is now carrying out a new share issue of 3,624,518 shares with preferential rights for the shareholders. This issue provides the company with approximately SEK 8.3 million. Shareholders of record date October 13, 2016 will receive information from your...Intervacc AB (publ) acquires Nordvacc
Stockholm, March 24, 2014 Press release Intervacc AB (publ) acquires Nordvacc Läkemedel AB and creates a leading player within the veterinary pharmaceutical market in Scandinavia and the Baltic countries. By the acquisition, Intervacc complements its on-going research...Nyhetstjänster
